Results of ASCT in patients with transformed FL
| Author . | No. of patients . | Median follow-up, mo . | PFS . | OS . |
|---|---|---|---|---|
| Cao et al15 | 17 | 45 | 49% at 5 y | 50% at 5 y |
| Friedberg et al23 | 27 | 36 | 46% at 5 y | 58% at 5 y |
| Foran et al24 | 27 | 29 | 52% at 4 y | 50% at 8.5 y |
| Williams et al253-150 | 50 | 59 | 30% at 5 y | 51% at 5 y |
| Chen et al27 | 35 | 52 | 50% at 21 mo | 37% at 5 y |
| Author . | No. of patients . | Median follow-up, mo . | PFS . | OS . |
|---|---|---|---|---|
| Cao et al15 | 17 | 45 | 49% at 5 y | 50% at 5 y |
| Friedberg et al23 | 27 | 36 | 46% at 5 y | 58% at 5 y |
| Foran et al24 | 27 | 29 | 52% at 4 y | 50% at 8.5 y |
| Williams et al253-150 | 50 | 59 | 30% at 5 y | 51% at 5 y |
| Chen et al27 | 35 | 52 | 50% at 21 mo | 37% at 5 y |
PFS indicates progression-free survival from HDT; OS, overall survival from HDT.
For the European Bone Marrow Transplantation Registry.